A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma
Sponsor: |
TriSalus Life Sciences |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT6585 |
U.S. Govt. ID: |
NCT04935229 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to determine the best level of dose of SD-101 given by hepatic artery infusion (HAI, a method of putting medication directly into your liver) with using Pressure-Enabled Drug Delivery (PEDD) alone or in combination with nivolumab and/or ipilimumab. Also to find out what effects (both good and bad) SD-101 given by HAI with PEDD has on you and your cancer when given alone or with nivolumab and/or ipilimumab.
This study is closed
Investigator
Alexander Wei, MD
Are you 18 years of age or older? |
Yes |
No |
Have you been diagnosed with metastatic uveal melanoma (eye cancer) with liver only or liver-dominant disease? |
Yes |
No |
Have you previously received SD-101? |
Yes |
No |